A “promising” new drug which has been shown to slow down progression of motor neurone disease (MND) could be a turning point for patient care, according to scientists involved in clinical trials.
Some patients with a faulty SOD1 gene, who took part in the global phase III trial, reported better mobility and lung function a year after taking the drug tofersen.
